Viewing Study NCT02212561


Ignite Creation Date: 2025-12-24 @ 12:20 PM
Ignite Modification Date: 2026-05-31 @ 4:42 PM
Study NCT ID: NCT02212561
Status: COMPLETED
Last Update Posted: 2020-03-26
First Post: 2014-07-30
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
Sponsor: St. Jude Children's Research Hospital
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Acute Myeloid Leukemia (AML) View
None Acute Lymphoblastic Leukemia (ALL) View
None Myelodysplastic Syndrome (MDS) View
None Mixed Phenotype Acute Leukemia (MPAL) View
Keywords: